Therapeutic adherence in multiple sclerosis. Example of the first line therapy drugs given in injections Review article
Article Sidebar
Published:
Mar 31, 2018
Keywords:
therapeutic adherence, multiple sclerosis
Main Article Content
Abstract
Adherence is an important issue in many chronic diseases. Many of those diseases remain symptomless for many years. If patient refuse to take medicines the clinical consequences often will appear after many years. In case of others the consequences appear very soon after drug discontinuation. In the article authors review selected studies concerning first line injectable therapy adherence in multiple sclerosis patients.
Article Details
How to Cite
Wełnicki , M., Mirowska-Guzel, D., & Mamcarz , A. (2018). Therapeutic adherence in multiple sclerosis. Example of the first line therapy drugs given in injections. Medycyna Faktow (J EBM), 11(1(38), 70-75. https://doi.org/10.24292/01.MF.0118.11
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Horne R., Weinman J., Barber N. et al.: Concordance, adherence and compliance in medicine taking. Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R&D (NCCSDO). December 2005.
2. Mossakowska M., Więcek A., Błędowski P.: Aspekty medyczne, psychologiczne, socjologiczne i ekonomiczne starzenia się ludzi w Polsce. Termedia, Poznań 2012.
3. Pruijm M., Schneider M.P., Burnier M.: Współpraca pacjent–lekarz a farmakologiczne leczenie nadciśnienia tętniczego. Choroby Serca i Naczyń 2010; 7(4): 159-164.
4. Biesaga T.: Autonomia lekarza i pacjenta a cel medycyny. Medycyna Praktyczna 2005; 6: 20-24.
5. Polskiego pacjenta portret własny. Raport o przestrzeganiu zaleceń terapeutycznych przez polskich pacjentów wykonany na zlecenie Fundacji Na Rzecz Wspierania Polskiej Farmacji i Medycyny przez Pentro Research International.
6. Hołub G.: Pacjent jako osoba. W: Chańska W., Hartman J. (red.): Bioetyka w zawodzie lekarza. Wolters Kluwer, Warszawa 2010: 39-48.
7. Bryl W., Cymerys M., Kujawska-Łuczak M., Pupek-Musialik D.: Program edukacyjny jako element poprawiający współpracę lekarza z pacjentem w terapii nadciśnienia tętniczego. Nowiny Lekarskie 2004; 73(1): 42-45.
8. Cohen B.A., Coyle P.K., Leist T. et al.: Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse. Mult. Scler. Relat. Disord. 2015; 4(1): 75-82.
9. Ebers G.C.: Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J. Neurol. Neurosurg. Psychiatry 2010; 81: 907-912.
10. Goodin D.S. Jones J., Li D. et al: Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS. PloS One 2011; 6(11): e22444.
11. Siger M., Durko A, Nicpan A. et al.: Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity. J. Neurol. Sci 2011; 303(1-2): 50-52.
12. O’Rourke K.E., Hutchinson M.: Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult. Scler. 2005; 11: 46-50.
13. Treadaway K., Cutter G., Salter A. et al.: Factors that influence adherence with disease-modifying therapy in MS. J. Neurol. 2009; 256(4): 568-576.
14. Correia I., Marques I.B., Sousa M. et al.: Predictors of first-line treatment persistence in a Portuguese cohort of relapsing-remitting multiple sclerosis. J. Clin. Neurosci. 2016; 33: 73-78.
15. Zhornitsky S., Greenfield J., Koch M.W.: Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study. PLoS One 2015; 10(4):e0123824.
16. Bayas A., Ouallet J.C., Kallmann B.: Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opin. Drug Deliv. 2015; 12(8): 1239-1250.
17. Lapierre Y., O’Connor P., Devonshire V.: Canadian Experience with Fingolimod: Adherence to Treatment and Monitoring. Can. J. Neurol. Sci. 2016; 43(2): 278-83.
18. Bergvall N., Petrilla A.A., Karkare S.U. et al.: Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. J. Med. Econ. 2014; 17(10):696-707.
19. Settle J.R., Maloni H.W., Bedra M. et al.: Monitoring medication adherence in multiple sclerosis using a novel web-based tool: A pilot study. J. Telemed. Telecare 2016; 22(4): 225-233.
20. Tintore M., Rovira À., Río J. et al.: Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 2015; 138(Pt 7): 1863-1874.
21. Pozzilli C., Schweikert B., Ecari U. et al.: Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study. J. Neurol. 2012; 259(11): 2319-2328.
22. Hupperts R., Becker V., Friedrich J. et al.: Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction. Expert Opin. Drug Deliv. 2015; 12(1): 15-25.
23. Devonshire V.A., Feinstein A., Moriarty P.: Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study. BMC Res. Notes 2016; 9: 148.
24. Bruce J., Bruce A., Lynch S. et al.: A pilot study to improve adherence among MS patients who discontinue treatment against medical advice. J. Behav. Med. 2016; 39(2): 276-287.
2. Mossakowska M., Więcek A., Błędowski P.: Aspekty medyczne, psychologiczne, socjologiczne i ekonomiczne starzenia się ludzi w Polsce. Termedia, Poznań 2012.
3. Pruijm M., Schneider M.P., Burnier M.: Współpraca pacjent–lekarz a farmakologiczne leczenie nadciśnienia tętniczego. Choroby Serca i Naczyń 2010; 7(4): 159-164.
4. Biesaga T.: Autonomia lekarza i pacjenta a cel medycyny. Medycyna Praktyczna 2005; 6: 20-24.
5. Polskiego pacjenta portret własny. Raport o przestrzeganiu zaleceń terapeutycznych przez polskich pacjentów wykonany na zlecenie Fundacji Na Rzecz Wspierania Polskiej Farmacji i Medycyny przez Pentro Research International.
6. Hołub G.: Pacjent jako osoba. W: Chańska W., Hartman J. (red.): Bioetyka w zawodzie lekarza. Wolters Kluwer, Warszawa 2010: 39-48.
7. Bryl W., Cymerys M., Kujawska-Łuczak M., Pupek-Musialik D.: Program edukacyjny jako element poprawiający współpracę lekarza z pacjentem w terapii nadciśnienia tętniczego. Nowiny Lekarskie 2004; 73(1): 42-45.
8. Cohen B.A., Coyle P.K., Leist T. et al.: Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse. Mult. Scler. Relat. Disord. 2015; 4(1): 75-82.
9. Ebers G.C.: Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J. Neurol. Neurosurg. Psychiatry 2010; 81: 907-912.
10. Goodin D.S. Jones J., Li D. et al: Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS. PloS One 2011; 6(11): e22444.
11. Siger M., Durko A, Nicpan A. et al.: Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity. J. Neurol. Sci 2011; 303(1-2): 50-52.
12. O’Rourke K.E., Hutchinson M.: Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult. Scler. 2005; 11: 46-50.
13. Treadaway K., Cutter G., Salter A. et al.: Factors that influence adherence with disease-modifying therapy in MS. J. Neurol. 2009; 256(4): 568-576.
14. Correia I., Marques I.B., Sousa M. et al.: Predictors of first-line treatment persistence in a Portuguese cohort of relapsing-remitting multiple sclerosis. J. Clin. Neurosci. 2016; 33: 73-78.
15. Zhornitsky S., Greenfield J., Koch M.W.: Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study. PLoS One 2015; 10(4):e0123824.
16. Bayas A., Ouallet J.C., Kallmann B.: Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opin. Drug Deliv. 2015; 12(8): 1239-1250.
17. Lapierre Y., O’Connor P., Devonshire V.: Canadian Experience with Fingolimod: Adherence to Treatment and Monitoring. Can. J. Neurol. Sci. 2016; 43(2): 278-83.
18. Bergvall N., Petrilla A.A., Karkare S.U. et al.: Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. J. Med. Econ. 2014; 17(10):696-707.
19. Settle J.R., Maloni H.W., Bedra M. et al.: Monitoring medication adherence in multiple sclerosis using a novel web-based tool: A pilot study. J. Telemed. Telecare 2016; 22(4): 225-233.
20. Tintore M., Rovira À., Río J. et al.: Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 2015; 138(Pt 7): 1863-1874.
21. Pozzilli C., Schweikert B., Ecari U. et al.: Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study. J. Neurol. 2012; 259(11): 2319-2328.
22. Hupperts R., Becker V., Friedrich J. et al.: Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction. Expert Opin. Drug Deliv. 2015; 12(1): 15-25.
23. Devonshire V.A., Feinstein A., Moriarty P.: Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study. BMC Res. Notes 2016; 9: 148.
24. Bruce J., Bruce A., Lynch S. et al.: A pilot study to improve adherence among MS patients who discontinue treatment against medical advice. J. Behav. Med. 2016; 39(2): 276-287.